Climb Bio, Inc. (CLYM)

Climb Bio, Inc.'s stock price has increased by over 521% in the past six months. Key events impacting the stock price include the FDA Fast Track Designation for Budoprutug, positive topline Phase 1 subcutaneous data for Budoprutug, Q1 2026 results beating EPS estimates, a $110 million private placement, and bullish analyst coverage.

As a clinical-stage biotechnology company, Climb Bio, Inc. does not currently have commercialized products or services. Therefore, the concept of demand seasonality is not applicable to Climb Bio, Inc. The company's focus is on the research and development of therapeutics, with its progress and valuation tied to clinical trial milestones and regulatory approvals rather than seasonal consumer purchasing patterns.

Climb Bio, Inc. is a clinical-stage biotechnology company focused on developing therapeutics for immune-mediated diseases. The company operates in the Healthcare sector, specifically in Biotechnology and Medical Research, with a focus on Drug Discovery. Its pipeline centers on monoclonal antibody product candidates designed to modulate B-cell biology, including Budoprutug and CLYM116.

Climb Bio, Inc. is headquartered in Wellesley Hills, Massachusetts, United States. The company has a global clinical development presence, with 20 regulatory clearances to conduct clinical trials and 45 trial sites worldwide for its Budoprutug and CLYM116 programs, including regulatory clearance in China.

Information directly pertaining to Climb Bio, Inc.'s general brand reputation is not explicitly available. However, the company's reputation in the past year appears to be generally favorable, primarily driven by its clinical development progress, positive financial updates, and strong stock performance. The significant increase in stock price and positive analyst ratings suggest a favorable perception among investors and market observers. There have been no specific events reported that have negatively impacted Climb Bio, Inc.'s reputation in the past year.

Climb Bio, Inc. has a mixed ownership structure. Retail investors constitute the largest shareholder group, holding approximately 36% of the company's stock. Institutional investors collectively own between 53.64% and 69.76% of the stock, while insiders hold around 13.15% to 24.12%. Major institutional owners include Ra Capital Management, L.p., MPM Oncology Impact Management LP, Price T Rowe Associates Inc /md/, Vanguard Group Inc, ADAR1 Capital Management, LLC, Affinity Asset Advisors, LLC, Kynam Capital Management, LP, Great Point Partners Llc, Sphera Funds Management Ltd., and Point72 Asset Management, L.P. Ai Eti LLC is noted as a significant individual shareholder.